

Guo Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9677266/publications.pdf>

Version: 2024-02-01

23
papers

314
citations

1163117

8
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

503
citing authors

#	ARTICLE	IF	CITATIONS
1	Similarities and Differences in Gastrointestinal Physiology Between Neonates and Adults: a Physiologically Based Pharmacokinetic Modeling Perspective. <i>AAPS Journal</i> , 2014, 16, 1162-1166.	4.4	60
2	Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 314-326.	1.3	59
3	Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. <i>Gut</i> , 2021, 70, 1806-1808.	12.1	35
4	MicroRNAs in the Progress of Diabetic Nephropathy: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-9.	1.2	33
5	Ethnic-Specific In Vitro-In Vivo Extrapolation and Physiologically Based Pharmacokinetic Approaches to Predict Cytochrome P450-Mediated Pharmacokinetics in the Chinese Population: Opportunities and Challenges. <i>Clinical Pharmacokinetics</i> , 2014, 53, 197-202.	3.5	19
6	Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1948-1956.	3.3	18
7	Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults. <i>Clinical Pharmacokinetics</i> , 2019, 58, 927-941.	3.5	18
8	Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye. <i>Lancet Oncology</i> , The, 2014, 15, e469-e470.	10.7	17
9	Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies. <i>Drug Discovery Today</i> , 2019, 24, 845-857.	6.4	8
10	Fasting conditions in clinical oncology trials and drug labelling. <i>Lancet Oncology</i> , The, 2017, 18, e506.	10.7	6
11	Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 543-551.	1.9	6
12	Pooled Analysis of Gastric Emptying in Patients With Obesity: Implications for Oral Absorption Projection. <i>Clinical Therapeutics</i> , 2021, 43, 1768-1788.	2.5	6
13	The role of a meal on gastrointestinal toxicity and maximum tolerated dose. <i>Lancet Oncology</i> , The, 2016, 17, e2-e3.	10.7	5
14	Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 404-408.	0.9	5
15	Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flow". <i>Clinical Pharmacokinetics</i> , 2016, 55, 133-137.	3.5	4
16	Model-Informed Approaches for Alternative Aripiprazole Dosing Regimens and Missed Dose Management: Towards Better Adherence to Antipsychotic Pharmacotherapy. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 471-473.	1.6	4
17	Conflicting meal recommendations for oral oncology drugs: pose risks to patient care?. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 833-842.	1.9	3
18	Abundance and Associated Variations of Cytochrome P450 Drug-Metabolizing Enzymes in the Liver of East Asian Adults: A Meta-Analysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 225-233.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 151-156.	1.6	2
20	Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1239-1240.	9.1	1
21	Reproducing prolonged time to peak bisoprolol concentration by PBPK modeling with lysosomal trapping in enterocytes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 5-6.	2.5	1
22	Use of proton pump inhibitors and adverse clinical outcomes. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2452-2453.	2.4	1
23	Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19. <i>European Journal of Clinical Pharmacology</i> , 2022, , .	1.9	0